-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5

Benzinga·11/17/2025 12:26:27
Listen to the news
Leerink Partners analyst Marc Goodman initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.